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Background: The lack of a general clinic-relevant model for human cancer is a major 
impediment to the acceleration of novel therapeutic approaches for clinical use. We 
propose to establish and characterize primary human hepatocellular carcinoma (HCC) 
xenografts that can be used to evaluate the cytotoxicity of adoptive chimeric antigen 
receptor (CAR) T cells and accelerate the clinical translation of CAR T cells used in HCC.
Methods: Primary HCCs were used to establish the xenografts. The morphology, immu-
nological markers, and gene expression characteristics of xenografts were detected and 
compared to those of the corresponding primary tumors. CAR T cells were adoptively 
transplanted into patient-derived xenograft (PDX) models of HCC. The cytotoxicity of 
CAR T cells in vivo was evaluated.
results: PDX1, PDX2, and PDX3 were established using primary tumors from three 
individual HCC patients. All three PDXs maintained original tumor characteristics in 
their morphology, immunological markers, and gene expression. Tumors in PDX1 grew 
relatively slower than that in PDX2 and PDX3. Glypican 3 (GPC3)-CAR T cells efficiently 
suppressed tumor growth in PDX3 and impressively eradicated tumor cells from PDX1 
and PDX2, in which GPC3 proteins were highly expressed.
conclusion: GPC3-CAR T cells were capable of effectively eliminating tumors in PDX 
model of HCC. Therefore, GPC3-CAR T cell therapy is a promising candidate for HCC 
treatment.
Keywords: cell therapy, T cells, car, hepatocellular carcinoma, PDX
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inTrODUcTiOn
Hepatocellular carcinoma (HCC) accounts for 90% of primary 
liver cancers and is one of the deadliest cancers in Asia (1–3). 
Current curative approaches for liver cancer mainly involve par-
tial liver resection, liver transplantation, chemotherapy, and tran-
sarterial chemoembolization (4, 5). Despite enormous advances 
in the diagnosis and treatment of liver cancer in the recent 
decades, the 5-year survival rate has remained at about 10% (6, 
7). Thus, more novel potential strategies, such as immunotherapy 
with genetic engineering of T cells to express chimeric antigen 
receptor (CAR), are now being tested in clinical trials (http://
www.clinicaltrials.gov). For accelerating the steps of clinical tri-
als, careful preclinical evaluations in models that closely mirror 
the clinical situation are urgently required.
Patient-derived xenografts (PDXs) refer to a procedure 
in which cancerous tissue from a patient’s primary tumor is 
implanted directly into an immunodeficient mouse (8). This tech-
nique offers several advantages over standard cell line xenograft 
models. Unlike cancer cell lines, primary tumor cells are directly 
derived from human tissues and are not subjected to frequent 
high-serum environments and passages. Thus, PDX models are 
more biologically stable when passaged in mice in terms of muta-
tional status, gene expression patterns, drug responsiveness, and 
tumor heterogeneity (9). Despite these benefits, only two studies 
report the use of PDX models of HCCs in drug testing (10, 11). 
No study has yet examined the use of CAR T cells in PDX models 
of HCC. Thus, it is necessary to carry out preclinical evaluation of 
novel CAR T cells against HCCs in PDX models.
It has been shown that glypican-3 (GPC3), a 580-AA heparan 
sulfate proteoglycan, expresses in 75% of HCC samples but not 
in healthy liver or other normal tissue (12). GPC3 is, therefore, 
a suitable target for CAR T cell therapy. Two previous studies 
showed the promising activity of GPC3-CAR T cells against HCC 
cell lines in vivo (13, 14). However, the capacity of GPC3-CAR T 
cells to eliminate HCC has not been evaluated in PDX models yet. 
In this study, we established and characterized primary human 
HCC xenografts to assess the cytotoxicity of adoptive GPC3-CAR 
T cells.
MaTerials anD MeThODs
establishment of hcc Xenografts
Written informed consent was obtained from 12 patients, and the 
study received ethics approval from the Research Ethics Board of 
GIBH and the Second Affiliated Hospital of Guangzhou Medical 
University. All experimental protocols were performed in accord-
ance with guidelines set by the China Council on Animal Care 
and the Ethics Committee of Animal Experiments at GIBH. The 
mice were provided with sterilized food and water ad  libitum 
and housed in negative pressure isolators with 12-hour light/
dark cycles. The isolation was performed following a previously 
described method with some modifications. The diagnosis of 
HCC was confirmed by histologic analysis in all cases. HCC tis-
sues were transplanted into NOD/SCID/IL2rg−/− (NSI) mice that 
were sourced from Li’s lab (15–17). Primary HCC tumors were 
placed in RPMI 1640 in an ice bath. Thin slices of tumor were 
diced into ~25 mm3 pieces. The tissue was transplanted subcuta-
neously in the right flank of 8-week-old male NSI mice. Growth 
of the established tumor xenografts was monitored at least twice 
weekly through measurement of the length (a) and width (b) of 
the tumor. The tumor volume was calculated as (a × b2)/2. For 
serial transplantation, tumor-bearing animals were anesthetized 
with diethyl ether and sacrificed via cervical dislocation. Tumors 
were minced under sterile conditions and transplanted in succes-
sive NSI mice as described earlier.
For the Huh-7 and HepG2 xenograft model, mice were 
inoculated subcutaneously with 2 × 106 Huh-7 cells on the right 
flank. When the tumor volume was approximately 50–100 mm3, 
the xenografts were randomly allocated into two groups, and 
the mice were given intravenous injection of human GPC3-
CAR T or Control-CAR T cells in 200-µL phosphate-buffered 
saline solution as indicated. The tumor volume was calculated 
as (a × b2)/2.
genes and lentiviral Vectors
To generate CARs-targeting GPC3, the genes of anti-GPC3 scFv, 
based on GC33 antibodies (18) and anti-CD19 scFv as Control 
ScFv, were first synthesized and subcloned in frame into lentiviral 
vectors containing expression cassettes encoding an IgM signal 
peptide and CD3ζ, CD28ζ, and 4-1BBζ signaling domains under 
the control of an EF-1α promoter. The sequence of each cloned 
CAR was verified via sequencing.
cell lines and reagents
A total of 293 T cells were used for lentivirus production and were 
cultured with DMEM (Gibco, Life Technologies), supplemented 
with 10% fetal bovine serum (FBS), 2 mM l-glutamine, 50 µM 
β-mercaptoethanol, 100 IU/mL of penicillin, and 100 IU/mL of 
streptomycin. HepG2 (HB-8065, purchased from ATCC), Huh-7 
(gifted from Dr. Xiaoping Chen, GIBH), and A549 (CCL-185, 
purchased from ATCC) were transduced with a lentiviral vec-
tor co-expressing GFP and luciferase. HepG2-GL (HCC line, 
stably transfected with GFP and luciferase), Huh7-GL (HCC 
line, stably transfected with GFP and luciferase), and A549-GL 
(lung adenocarcinoma line, stably transfected with GFP 
and luciferase) cells were cultured with DMEM (Gibco, Life 
Technologies) supplemented with 10% FBS, 2 mM l-glutamine, 
50 µM β-mercaptoethanol, 100 IU/mL of penicillin, and 100 IU/
mL of streptomycin. Human recombinant interleukin (IL)-2 was 
obtained from Peprotech. Polyethylenimine, an efficient transfec-
tion agent, was purchased from Life Technologies. Anti-GPC3 
and anti-AFP were purchased from Santa Cruz Biotechnology, 
anti-CD3 (BV421) from Biolegend, and the remainder from 
eBioscience: CD45RO (Clone UCHL1), CD38 (clone HIT2), 
CD45 (clone HI30), CD19 (clone HIB19), CD5 (clone UCHT2), 
CD137 (clone 4B4-1), CD62L (clone DREG-56), CCR7 (clone 
3D12), CD3 (clone OKT3), CD86 (clone IT2.2), PD-1 (clone 
eBioJ105), CD44 (clone IM7), TIM3 (clone F38-2E2), CD25 
(clone BC96), CD49d (clone 9F10), CD18 (clone 6.7), CD27 
(clone O323), CD163 (clone eBioGHI/61), CD326 (clone 1B7), 
CD66b (clone G10F5), CD3 (clone WM-59), CD206 (clone 19.2), 
CD80 (clone16-10A1), CD24 (clone eBioSN3), CD42b (clone 
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HIP1), CD36 (clone eBioNL07), CD127 (clone eBioRDR5), 
LAG3 (clone 3DS223H), CD107a (clone eBioH4A3), CTLA4 
(clone 14D3), CD28 (clone CD28.2), CD56 (clone TULY56), 
CD49f (clone eBioGoH3), HLA-DR (clone L243), CD4 (clone 
OKT4), and CD8 (clone OKT8).
isolation, Transduction, and expansion of 
Primary human T lymphocytes
Peripheral mononuclear cells (PBMCs) were separated via density 
gradient centrifugation (Lymphoprep, Stem Cell Technologies, 
Vancouver, BC, Canada). Primary human T cells were isolated 
from PBMCs via negative selection using the pan T Isolation Kit 
(Miltenyi Biotec, Germany). T cells were cultured in RPMI 1640 
supplemented with 10% FCS (Gibco, Life Technologies), 100-U/
mL penicillin, and 100  g/mL streptomycin sulfate (R10) and 
were stimulated with particles coated with anti-CD3/anti-CD28 
antibodies (Miltenyi Biotec, Germany) at a cell-to-bead ratio of 
1:2. Approximately 72 h after activation, T cells were transfected 
with supernatant containing lentiviral vectors expressing Control 
or GPC3-CARs. After transduction for 12 h, T cells were cultured 
with R10 medium supplemented with IL-2 (300 IU/mL). T cells 
were fed with fresh media every 2  days and were used within 
21 days of expansion in all experiments.
cytotoxicity assays
The target cells HepG2-GL, Huh-7-GL, and A549-GL were 
incubated with Control-CAR T or GPC3-CAR T cells at the 
indicated ratios in triplicate wells in U-bottomed, 96-well plates. 
Target cell viability was monitored 24 h later by adding 100 µL/
well substrate d-Luciferin (potassium salt; Cayman Chemical, 
USA) resolved at 150  µg/mL. The background luminescence 
was negligible (<1% the signal from the wells with only target 
cells). The viability percentage (%) was, therefore, equal to the 
experimental signal/maximal signal, and the killing percentage 
was equal to 100 − viability percentage.
enzyme-linked immunosorbent assay 
(elisa)
Enzyme-Linked Immunosorbent Assay kits for IL-2 and 
interferon-γ were purchased from eBioscience, San Diego, CA, 
USA, and all ELISAs were conducted in accordance with the 
manuals provided. Control-CAR T and GPC3-CAR T cells 
were co-cultured at a 1:1 E/T ratio for 24  h in duplicate wells, 
from which the supernatant was collected and measured for the 
concentrations of IL-2 and IFN-γ.
Quantitative real-Time Polymerase chain 
reaction (Pcr)
mRNA was extracted from cells with TRIzol reagent (Qiagen, 
Stockach, Germany) and reverse transcribed into cDNA using 
the PrimeScript™ RT reagent Kit (Takara, Japan). All reactions 
were performed with TransStart Tip Green qPCR SuperMix 
(TransGene, Beijing, China) on a Bio-Rad CFX96 real-time PCR 
machine (Bio-Rad, Hercules, CA, USA), using the primers shown 
in Table S1 in Supplementary Material. Delta CT calculations 
were relative to β-actin and corrected for PCR efficiencies.
Flow cytometry
Flow cytometry for the GFP% of transduced T cells and for 
GPC3 and PD-L1 expression on HCC cells was performed on 
a C6 cytometer and analyzed using the FlowJo software. The 
PBMCs, spleens, and bone marrow (BM) from xenograft mice 
were treated with a red blood cell lysis buffer (Biolegend), and 
the cells were stained with anti-hCD3, hCD4, and hCD8 analyzed 
on a Fortessa cytometer (BD Biosciences). All FACS staining was 
performed on ice for 30 min and washed with PBS containing 
2% FBS before cell cytometry. Mouse tissues were weighed and 
harvested into ice-cold RPMI 1640. The tissues were manually 
morselized with a scalpel and then mechanically disaggregated 
through 40- to 100-mm filters.
histological analysis
Organ or tissue samples were fixed in 10% neutral formalin, 
embedded in paraffin, sectioned at 4-µm thickness, and stained 
with hematoxylin and eosin or antibodies (GPC3 and AFP). 
Images were obtained on a microscope (Leica DMI6000B, Leica 
Microsystems, Wetzlar, Germany).
statistics
The data are presented as the mean ±  SEM. The results were 
analyzed via an unpaired Student’s t-test (two-tailed). Statistical 
significance was defined by a P value of less than 0.05. All statisti-
cal analyses were performed using the Prism software version 6.0 
(GraphPad).
resUlTs
establishment and characterization of 
hccs from PDXs
Of the 12 models, 6 did not grow in the first generation (P1). 
PDXs of HCC were successfully engrafted from six PDXs in 
immunodeficient mice (NSI, NOD/SCID-IL2rg−/−). Of these, 
three xenografts were propagated beyond the third generation 
(P3) (Figure 1A), whereas three tumors were still growing in the 
first generation (P1). Taken together, a success rate of 25% was 
reached when the third generation was considered successfully 
engrafted. An overview of the successfully growing PDX models 
and their clinical characteristics of the original patients are shown 
in Table 1.
To validate the established PDX models, we compared their 
morphology, immunological markers (GPC3 and AFP), and 
gene expressions with those of the corresponding primary tumor. 
Histologic evaluation of the xenografts revealed tumor tissue 
with morphologic characteristics like those of the original pri-
mary human tumor (Figure 1B). Immunologic markers of liver 
tumors such as GPC3 and APF were detected in both primary 
patient tumors and xenografts (Figure 1C). Quantitative reverse 
transcription PCR was performed to characterize the mRNA 
expression level of some tumor-related genes in xenografts and 
primary tumor (Figure 1D). These genes are associated with car-
cinogenesis, aggression, and characterization of HCCs (19, 20). 
Unsupervised hierarchical clustering of selected transcriptional 
profiles confirmed that all patients and xenograft pairs cluster 
FigUre 1 | characterization of patient-derived xenograft (PDX) model of hepatocellular carcinoma. (a) Patient-derived xenografts (PDXs) were 
established, and tumor growth was measured at a given time for each PDX xenograft. Tumor volume was calculated as (a × b2)/2, the length (a), and width (b) of 
tumor. (B,c) H&E and IHC staining tissue of primary tumor and PDXs. The xenograft demonstrates morphology, glypican 3, and AFP staining consistent with the 
original human tumor. Brown color indicates positive staining. IgG was used as a negative control. Scale bar is 50 μm. (D) mRNA expression level of tumor-related 
genes [MET (MET proto-oncogene, receptor tyrosine kinase), CTNNB1 (catenin beta 1), AXIN1 (axin 1), TP53 (tumor protein p53), RB1 (RB transcriptional 
corepressor 1), PTEN (phosphatase and tensin homolog), BCL2 (BCL2, apoptosis regulator), AFP (alpha fetoprotein), KRT19 (keratin 19), CDKN2A (cyclin-
dependent kinase inhibitor 2A), CDKN1B (cyclin-dependent kinase inhibitor 1B), and CCND1 (cyclin D1)] in primary tumor and PDXs. Results represent mean ± SD 
of three individual experiments.
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TaBle 1 | clinical information of patients.
hcc sex age (years) site hBsag Metastasis histologic grade PD-l1 aFP (Ui/ml) Xenografts
Patient 1 Male 47 Left lobe − No III − 4 3rd
Patient 2 Female 47 Right lobe + No IV − 2.15 3rd
Patient 3 Male 53 Right lobe + Intrahepatic IV + 384.99 3rd
Patient 4 Male 50 Right lobe + No III − 3.85 1st
Patient 5 Male 60 Right lobe + No III + 1.68 1st
Patient 6 Male 67 Left lobe − No III − 62.54 1st
FigUre 2 | construction of chimeric anti-glypican 3 (gPc3) vectors and generation of gPc3-chimeric antigen receptor (car) T cells. (a) Schematic 
representation of a lentiviral vector encoding the signal peptide, anti-GPC3 scFv, CD28 transmembrane domain, 4-1BB costimulatory endodomain, and CD3ζ 
signaling domain along with eGFP using 2A. (B) A representative of GPC3-CARs expression on human T cells transduced with lentivirus was analyzed using flow 
cytometry, which detected eGFP at days 7 and 14. (c) Transduction efficiency. Results represent mean ± SD of six individual experiments. No difference was 
detected between the percentages of GPC3-CAR T and Control CAR T. (D) The expansion of transduced T cells in vitro from day 0 to 21. Results represent 
mean ± SD of three individual experiments.
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together (Figure S1 in Supplementary Material). Collectively, 
our results indicate that PDX of HCCs in the mice recapitulate 
the original disease and remain stable through three serial 
transplantations.
T cells engineered to express  
gPc3-cars
The sequencing encoding the anti-GPC3 scFv (Figure S2A in 
Supplementary Material) was cloned in frame into lentivirus 
vectors containing CAR expression cassettes with CD28, 4-1 BB, 
and CD3ζ endodomains (Figure 2A). For the generation of T cell 
populations that expressed the anti-hGPC3-CAR, a two-step 
optimal expansion protocol was developed. CD3- and CD28-
activated T cells after 72 h were transduced with the GPC3-CAR 
construct to generate GPC3-CAR T cells. The expression of 
CARs was measured via flow cytometry through eGFP expres-
sion. CARs were stably expressed from day 7 to day 14 with 
no significant difference (Figure  2B). The frequency of CAR 
expression was 58.6% for CD19-CAR and 49.2% for GPC3-CAR 
(Figure 2C). Flow cytometric analysis using a goat anti-mouse 
F(ab)2 confirms that the expression of CAR molecules was 
consistent with eGFP (Figure S2B in Supplementary Material). 
The generated CAR T cells were >97% CD3-positive T cells, 
which consisted of CD4- and CD8-positive T cell subsets with 
the same ratio as the non-transduced T cells (Figures S3A–D in 
FigUre 3 | Phenotypic analysis and cytokines produced in glypican 3 (gPc3)-chimeric antigen receptor (car) T cells. (a) Flow cytometry comparison 
of the common surface phenotype of GPC3-CAR T cells (red line) at day 14 of culture with freshly isolated T cells (blue line). Black line represents the isotype control. 
Histogram overlays show 16 markers related to lymphocyte activation, differentiation, migration, adhesion, and exhaustion. (B) Interferon-γ and (c) interleukin-2 
were secreted by the indicated modified CAR T cells co-cultured with hepatocellular carcinoma cell lines and A549 for 24 h. Results represent triplicates. 
***P < 0.001 with T-test.
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Supplementary Material). In our optimal expansion protocol, T 
cells begin to expand at day 3 and continued to expand until day 
21. Reproducible expansion of 20- to 50-folds of T cell can be 
achieved at day 14 (Figure 2D). Collectively, these experiments 
established a robust two-step method to transduce and expand 
(up to 50-fold) CAR-transduced T cells from the peripheral blood 
of healthy donors.
Phenotypic and Functional 
characterization of gPc3-car T cells
To better define the phenotyping of CAR-transduced T lym-
phocytes after infection, we next performed 35 different cell 
surface markers. CAR T cells were compared at the beginning 
(day 0) and the middle (day 14) of the T cell culture process. 
We observed upregulation of the activation markers CD25 and 
CD27, the migration maker CCR7 (Figure 3A), and the costimu-
latory receptors CD86 (21) and CD137 (Figure 3A), which are 
indicators of enhanced proliferative potential of T cells. After 
in vitro culture, T cells acquired an intermediate effector memory 
phenotype with the progressive downregulation of CD28 and 
CD62L. Moreover, we observed upregulation or downregulation 
of multiple molecules involved in cell adhesion. CD18, CD44, 
and CD49d were upregulated, and CD49f, CD107a, and CD56 
were downregulated (Figure  3A). Notably, key inhibitory and 
exhaustion-associated molecules such as PD-1, CTLA-4, and 
TIM3 were upregulated (Figure 3A). Importantly, we found strik-
ingly similar CAR T cell phenotypes across all six tested donors, 
as illustrated in the heat map in Figure S3E in Supplementary 
Material. A hallmark function of activated T lymphocytes is 
the production of cytokines. To evaluate this production, we 
co-cultured CAR T cells with GPC3-positive HCC cell lines as 
target cells (Figure S4A in Supplementary Material). GPC3-CAR 
T cells secreted high levels of INF-γ and IL-2 after coincubation 
with only GPC3-positive targets (Figures  3B,C). These data 
collectively characterize CAR T cells as a highly reproducible cel-
lular product of activated lymphocytes, endowed with migratory 
potential and natural cytotoxic machinery.
effective serial Killing of gPc3-Positive 
human hcc cells by gPc3-car T cells
To test whether GPC3-CAR T cells could specifically recog-
nize and kill GPC3-positive targets, cytotoxicity assays were 
FigUre 4 | cytotoxicity of glypican 3 (gPc3)-chimeric antigen receptor (car) T cells against targeted cells in vitro. (a) Cytotoxicity of GPC3-CAR 
T cells was assayed by coincubation with Huh-7-GL (GPC3+), HepG2-GL (GPC3+), and A549-GL (GPC3−) cells at E:T ratios ranging from 1:3 to 5:1. (B) Serial killing 
of GPC3-CAR cells against Huh-7-GL and HepG2-GL cells at E: T ratios of 1:1 in indicated durations. Results represent mean ± SEM.
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performed by incubating the CAR T cells with GPC3-positive 
HCC cells (Huh-7and HepG2) and GPC3-negative cells (A549) 
(Figure S4A in Supplementary Material). GPC3-CAR T cells 
were highly cytotoxic against the GPC3-positive HCC cells, 
Huh-7, and HepG2. By contrast, GPC3-CAR T cells did not 
target GPC3-negtive cells (Figure 4A). These data demonstrate 
that GPC3-CAR T cells selectively target GPC3-positive tumor 
cells. It had been demonstrated that 4-1BB endodomains 
ameliorate exhaustion of CAR T cells (22). To further explore 
cytotoxic potency of GPC3-CAR T cells incorporating 4-1BB 
costimulatory domains, we performed a co-culture in which 
CAR T cells were restimulated with GPC3-positive HCC 
cells every 24 h for three consecutive days at E:T ratios of 1:1 
(23). Killing of Huh-7 and HepG2 hepatoma cells was only 
observed when GPC3-CAR was reconstituted (Figure  4B). 
Taken together, these results indicate that GPC3-CART cells 
displayed significantly specific and efficient cytotoxicity against 
GPC3-positive target cells.
adoptive Transfer of gPc3-car T cells 
suppresses hcc cell lines growth In Vivo
To explore the killing of GPC3-positive tumors by GPC3-CAR 
T cells in vivo, we used a subcutaneous xenograft model in which 
transplant tumors were established in immunodeficient mice 
using HepG2 and Huh-7 cell lines. Tumors were established 
for 7 days, and a tumor volume of approximately 50–100 mm3 
was obtained. The mice were then treated via adoptive transfer 
of GPC3-CAR T or Control-CAR T cells. Tumor growth 
was efficiently suppressed by intravenous injection of 5 ×  106 
GPC3-CAR T cells (n = 5), as compared to a control group that 
received Control transduced T cells (n = 5) (Figures 5A–D). We 
also detected human T cells in the PBMC and tumor tissues of 
mice with subcutaneous Huh-7 or HepG2 xenografts after T cell 
infusion (Figures 5E,F). The results show that GPC3-CAR T cells 
can efficiently suppress the growth of HCC cell lines in mice.
Patient-Derived hcc Xenograft is 
controlled by gPc3-car T cells
Patient-derived xenograft models preserve the heterogeneous 
pathological and genetic characteristics of the original patient 
tumors and may provide a precision preclinical model for immu-
notherapy evaluation. Our results show that GPC3 protein was 
highly expressed in xenografts of HCCs, so we tested the effect of 
GPC3-CAR T cells in these PDX models. In all three individual 
PDX models, 2.5 × 106 CAR T cells were given by intravenous 
injection twice after the tumor volume reached 50–100 mm3. The 
efficient antitumor effect was observed in the xenografts treated 
with GPC3-CAR T cells compared to the Control-CAR T cells 
(Figures  6A–F). We observed that GPC3–CAR T cells have 
better cytotoxicity in PDX1 and PDX2 than PDX3. We propose 
that the heterogenous nature of tumors can affect GPC3-CAR 
T  cells cytotoxicity to tumors in  vivo. Studies have shown that 
the highly expressed MET, CTNNB1, and CCND1 are associated 
with aggression of HCCs (24). MET, CTNNB1, and CCND1 are 
highly expressed in PDX3 than in PDX1 and PDX2 (Figure 1D). 
This result implies that PDX3 tumor cells are more aggressive. 
Programed cell death 1 (PD-1), an immunoinhibitory receptor 
belonging to the CD28 family, has been shown as a frequently 
used physiologic immunosuppressive mechanism by tumors to 
invade host immunity (25). Our results show that PD-L1 was 
highly expressed in PDX3 but not in PDX1 and PDX2 (Table 1). 
These results suggest that tumor aggression and immunosuppres-
sive molecules should be considered in CAR T cell therapy. T cell 
analysis also shows that GFP-positive T cells are higher in GPC3-
CAR T groups than in Control-CAR T groups (Figures 6G–I). 
Taken together, our results demonstrate that GPC3-CAR T cells 
FigUre 6 | glypican 3 (gPc3)-chimeric antigen receptor (car) T cells efficiently abolish growth of patient-derived xenografts (PDXs) of 
hepatocellular carcinoma. (a–c) Growth curve of PDX1, PDX2, and PDX3 (n = 5) treated with the Control- or GPC3-CAR T cells at indicated time point (arrow). 
At the end of the experiment, the tumors treated with GPC3-CAR T cells were significantly smaller than those in the Control group. (D–F) PDX1, PDX2, and PDX3 
tumor weights from the mice treated with CAR T cells at the end of the experiment. (g–i) GPC3-CAR T cells in tumors were significantly higher than Control-CAR 
T groups. Results represent mean ± SD. ***P < 0.001 with T-test.
FigUre 5 | cytotoxicity of glypican 3 (gPc3)-chimeric antigen receptor (car) T cells against hepatocellular carcinoma cell lines in xenografts. (a,B) 
Growth curve of Huh-7 and HepG2 xenografts (n = 5) treated with the Control- or GPC3-CAR T cells at indicated time point (arrow). At the end of the experiment, 
the tumors treated with GPC3-CAR T cells were significantly smaller than those in the Control group. (c,D) Huh-7 and HepG2 tumor weights from the mice treated 
with CAR T cells at the end of the experiment, respectively. (e,F) GPC3-CAR T cells in tumors were significantly higher than Control-CAR T groups. Results 
represent mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 with T-test.
8
Jiang et al. Evaluating GPC3-CAR T in PDX
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 690
9Jiang et al. Evaluating GPC3-CAR T in PDX
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 690
were able to efficiently suppress the growth of primary GPC3-
positive HCC in vivo.
DiscUssiOn
In this study, we report the establishment of three PDX models 
from primary HCC in NSI mice. The xenografts were success-
fully serially transplanted while preserving the characteristics of 
the original patient tumors. We observed that tumors in PDX2 
and PDX3 xenografts grow faster than that in PDX1. Our data 
suggest that their growth behavior is positively correlated with 
the expression levels of MET, CTNNB1, and CCND1. Previous 
studies show that MET and CTNNB1 act as oncogenes in HCCs 
and that CCND1 is the hallmark of cell cycle progression (19, 
26, 27).
Previous studies have shown that GPC3-CAR T cells efficiently 
eradicate liver cancer cells lines that possess a high level of GPC3 
expression in vivo (13, 14). Here, we observed that GPC3-CAR 
T cells were less effective to kill HCC cell lines in xenografts, 
compared to a previous report (13). A possible reason for this 
difference is that we used NOD/SCID/IL2−/− mice for xenotrans-
plantation, whereas the previous report used NOD/SCID mice, 
in which natural killer (NK) cells are active against tumor cells. 
By comparing the subcutaneous growth of Huh-7, we observed 
that Huh-7 cells grew faster in NOD/SCID/IL2−/− mice than in 
NOD/SCID mice. In addition, tumor-experienced T cells (28) 
can promote NK cell activity against tumors cells. It is likely that 
GPC3-CAR T cells may kill tumor cells in synergy with mouse 
NK cells.
Patient-derived xenograft models have been commonly used 
to test drug efficacies and identify biomarkers in a number of 
cancers, including liver, ovarian, pancreatic, breast, and prostate 
cancers (9). Previous studies have shown that tumors in PDX 
models are biologically stable and accurately reflect the histo-
pathology, gene expression, genetic mutations, and therapeutic 
response of the patient tumor (9). Several recent preclinical 
studies and clinical trials have demonstrated the efficient activity 
of CD19-CAR T cells against acute B lymphoblastic leukemia 
(29). However, CAR T cells that target solid tumors have so far 
demonstrated limited efficacy. To date, the most positive trials 
reported have used GD2 CARs to target neuroblastoma (3 of 11 
patients with complete remissions), HER2 CARs for sarcoma (4 
of 17 patients showing stable disease), and HER1 CARs for lung 
cancer (2 of 11 patients with partial responses) (30). We report 
that GPC3-CAR T cells impressively eradicated tumors from 
PDX1 and PDX2, which were less aggressive and were PD-L1 
negative. In contrast, GPC3-CAR T cells were less cytotoxicity to 
tumors in PDX3 that were more aggressive and highly expressed 
PD-L1, suggesting that we need to combine CAR T cell therapy 
and immune checkpoint inhibitors to achieve higher efficacy of 
eliminating PD-L1-positive HCC. Similarly, two recent reports 
showed that combining CAR therapy and PD-1 blockade was 
efficacious in breast cancer and mesothelioma models (31, 32). 
Downregulated expression of GPC3 in HCC cells may affect 
GPC3-CAR T-specific cytotoxicity to tumor cells. While our data 
show that the percentage of GPC3-positive cells was not changed 
in control and GPC3-CAR T treatment in vivo (Figures S4B,C in 
Supplementary Material).
In summary, we established and characterized three GPC3-
positive PDXs of HCC. We also show that GPC3-CAR T cells 
suppressed tumor growth but with different efficacies in the PDX 
models of the three individual patients. Therefore, PDX models 
can potentially be used to evaluate the efficacy of GPC3-CAR T 
cell therapy for treating HCC in individual patients.
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